Singapore, Sept. 25 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safe... और पढ़ें
Singapore, Sept. 25 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safe... और पढ़ें
Singapore, Sept. 25 -- The Health Sciences Authority received information related to the study titled 'DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLOZASIRAN... और पढ़ें
Singapore, Sept. 25 -- The Health Sciences Authority received information related to the study titled 'A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Inves... और पढ़ें
Singapore, Sept. 25 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) ... और पढ़ें
Singapore, Sept. 25 -- The Health Sciences Authority received information related to the study titled 'A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo i... और पढ़ें
Singapore, Sept. 25 -- The Health Sciences Authority received information related to the study titled 'Safety, immunogenicity and efficacy of low dose Nivolumab in adults living with HIV on antiretrov... और पढ़ें
Singapore, Sept. 25 -- The Health Sciences Authority received information related to the study titled 'A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Stud... और पढ़ें
Singapore, Sept. 25 -- The Health Sciences Authority received information related to the study titled 'Antigen Targeted T cell therapy for Relapsed/Refractory B cell Lymphomas'. The following are the ... और पढ़ें
Singapore, Sept. 25 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig ... और पढ़ें